Clin2
NCT06437574Possibly a fitRecruiting

Cholesterol-lowering and immune response in prostate cancer

Prostate Cancer

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
140 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have low- or intermediate-risk prostate cancer (PSA ≤ 20, stage T1c or T2, Gleason 3+3 to 4+3).
  • You are on active surveillance and scheduled for a follow-up biopsy.
  • You have not had any prior treatment for prostate cancer (like radiation, chemo, or hormone therapy).
  • You have at least one heart disease risk factor, such as age 50+, high blood pressure, high cholesterol, diabetes, smoking history, or family history of heart disease.
  • You can take a pill once a day and avoid drinking more than about a quart of grapefruit juice during the study.
  • You are not currently taking medications that interact with statins or ezetimibe, and have not had muscle pain from statins before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05586360Recruiting· Phase 2
Testing how a statin may change immune markers in prostate cancer

This Phase 2 study tests whether taking simvastatin can change “immune regulation” markers in men with intermediate- to high-risk localized prostate cancer. It also looks at whether this could help lower the risk of cancer coming back after planned prostate surgery.

Atlanta, Georgia
NCT03819101Recruiting· Phase 3
Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer

This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.

Olomouc
NCT05590624Recruiting
Mediterranean diet study for men on prostate cancer active surveillance

This trial studies how different controlled versions of a Mediterranean-style diet may affect prostate cancer-related metabolism in men choosing active surveillance. It may help participants understand whether diet changes influence markers linked to prostate cancer activity, while keeping them on a monitored care plan.

Cleveland, Ohio
NCT03769766Recruiting· Phase 3
Curcumin to help keep low-risk prostate cancer from worsening

This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.

Dallas, Texas
NCT06163924Recruiting
Heart risk reduction in prostate cancer patients on hormone therapy

This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.

Hong Kong
NCT07278362Not yet recruiting· Phase 4
Testosterone therapy for men with low-risk prostate cancer on active surveillance

This study tests whether testosterone replacement therapy can safely improve low testosterone symptoms in men with low-risk prostate cancer who are not receiving active treatment. You may be eligible if you have confirmed low testosterone and are being monitored without intervention.

Miami, Florida

Hear when a new Prostate cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.